Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Surmodics, Inc.

Surmodics, Inc. Common Stock

Surmodics is involved in medical device coatings and in vitro diagnostics. It provides customized coatings for medical devices and chemical components for in vitro diagnostic tests.

msh id	COM:SURMODICS
symbol	SRDX
name	Surmodics, Inc.
homepage url	https://www.surmodics.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	376
crunchbase url	-
linkedin url	-
founders	-

market cap	600.57M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.04
growth cost of revenue	0.01
growth depreciation and amortization	-0.07
growth ebitda	2.13
growth ebitda ratio	1.85
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	1.1
growth gross profit ratio	0.59

COM:SURMODICS

Surmodics

Last Close

39.17

21/11 21:00

Market Cap

600.57M

Beta: -

Volume Today

65.74K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	126.98M
cost of revenue	126.98M
depreciation and amortization	8.52M
ebitda	14.58M
ebitda ratio	0.11
eps	-0.11
eps diluted	-0.11
operating expenses	55.42M
operating income	5.15M
operating income ratio	0.04

accounts receivables	-977K
capital expenditure	-2.92M
cash at beginning of period	19M
cash at end of period	41.42M
inventory	14.84M
working capital ttm	63.33M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-